title: Canine myocardial reperfusion injury. Its reduction by the combined administration of superoxide dismutase and catalase.
abstract: Therapy directed against the toxic effects of reactive oxygen species may reduce the final extent of ischemic injury in otherwise viable tissue irreversibly injured by the abrupt reoxygenation of reperfusion. In four groups of dogs, superoxide dismutase plus catalase (groups I-III) or saline (controls) (group IV) was infused into the left atrium. Group I received the infusion for 2 hours, beginning 15 minutes before occlusion of the left circumflex coronary artery (90 minutes) and ending 15 minutes after reperfusion. Group II received the infusion for 1 hour starting 15 minutes before reperfusion. Group III received the infusion for 1 hour beginning 40 minutes after reperfusion. Dogs were killed the next day, and infarct size was determined by dissection and weighing, and confirmed histologically. Infarct size expressed as percent of the anatomic area at risk was: group I, 19.4 +/- 5.0; group II, 21.8 +/- 3.3; group III, 47.6 +/- 10.3; group IV, 43.6 +/- 3.5 (mean +/- SEM). Analysis of variance followed by Duncan's multiple range test showed that ultimate infarct size as assessed in groups I and II differed significantly (P less than 0.05) from that observed in the control animals in group IV, whereas infarct size between groups III and IV did not differ significantly (P greater than 0.05). The percent of left ventricle at risk did not differ between the four groups. The beneficial effects of superoxide dismutase plus catalase could not be explained by hemodynamic differences. Similar protection of jeopardized myocardium in groups I and II suggest that potentially viable tissue is salvaged by scavenging free radicals during early reperfusion.(ABSTRACT TRUNCATED AT 250 WORDS)
mesh_terms: D000818:Animals; D002374:Catalase / Q000008:administration & dosage*; D003327:Coronary Disease / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology*; D004285:Dogs; D004359:Drug Therapy, Combination; D006439:Hemodynamics / Q000187:drug effects; D008297:Male; D009203:Myocardial Infarction / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology*; D009206:Myocardium / Q000473:pathology; D010477:Perfusion; D013482:Superoxide Dismutase / Q000008:administration & dosage*
chemical_list: D002374:Catalase; D013482:Superoxide Dismutase